Maleki Arash, Sahawneh Haitham F, Ma Lina, Meese Halea, He Yuchen, Foster C Stephen
*Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts; †Ocular Immunology and Uveitis Foundation (OIUF), Weston, Massachusetts; ‡Columbia University, Department of Statistics, New York, New York; and §Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Retina. 2017 May;37(5):836-843. doi: 10.1097/IAE.0000000000001269.
To examine the efficacy and safety of infliximab therapy in the treatment for noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy.
Forty-four eyes of 23 patients with resistant noninfectious intermediate uveitis who were treated with infliximab infusions for a minimum period of 3 months were included. Demographic data, clinical data, and fluorescein angiography and optical coherence tomography findings were collected from the Massachusetts Eye Research and Surgery Institution database between August 2005 and February 2014. Clinical response, improvement in ancillary test findings, and major side effects were evaluated.
Nineteen patients (82.6%) achieved remission. The mean duration of treatment to induce remission was 3.99 ± 3.06 months (range, 2-14.7). Cystoid macular edema was the only complication observed during the course of the treatment in 1 eye (2.27%). One patient (4.3%) developed major side effects. None of the patients developed central or peripheral demyelinating neuropathies or multiple sclerosis. At 6 months after remission, logarithm of the minimum angle of resolution visual acuity (P = 0.006) and central macular thickness (P = 0.03) showed significant improvement in patients who achieved remission.
A significant number of patients achieved remission on infliximab therapy. The incidence of major side effects in our cohort was low.
研究英夫利昔单抗治疗对常规免疫调节治疗耐药的非感染性中间葡萄膜炎的疗效和安全性。
纳入23例耐药性非感染性中间葡萄膜炎患者的44只眼，接受英夫利昔单抗输注治疗至少3个月。收集2005年8月至2014年2月期间来自马萨诸塞州眼研究与手术机构数据库的人口统计学数据、临床数据、荧光素血管造影和光学相干断层扫描结果。评估临床反应、辅助检查结果的改善情况和主要副作用。
19例患者（82.6%）病情缓解。诱导缓解的平均治疗时间为3.99±3.06个月（范围2 - 14.7个月）。治疗过程中仅1只眼（2.27%）出现黄斑囊样水肿这一并发症。1例患者（4.3%）出现主要副作用。所有患者均未发生中枢或周围脱髓鞘性神经病变或多发性硬化。病情缓解6个月后，病情缓解的患者最小分辨角对数视力（P = 0.006）和黄斑中心厚度（P = 0.03）有显著改善。
大量患者接受英夫利昔单抗治疗后病情缓解。我们队列中主要副作用的发生率较低。
